azelaprag
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 12, 2016 (NCT03276728)
Timeline
Indications
Mechanism of action
- Apelin receptorAGONIST
APLNR agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc(OC)c1-n1c(NS(=O)(=O)[C@@H](C)[C@H](C)c2ncc(C)cn2)nnc1-c1cncc(C)c1- Mol. weight
- 523.62 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4866732 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06515418 | Phase 2 | Jun 27, 2024 | BioAge Labs, Inc., Eli Lilly |
| NCT06141889 | Phase 1 | Nov 30, 2023 | BioAge Labs, Inc. |
| NCT03318809 | Phase 1 | Dec 12, 2017 | Amgen |
| NCT03276728 | Phase 1 | Aug 12, 2016 | Amgen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 2 | 2 | 1 | 2016 |
| BioAge Labs, Inc. | For profit | 2 | 2 | 2 | 2023 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1